Cited by 500Immune cells in cancerImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

Open access

Kodumudi, Krithika N., Woan, Karrune, Gilvary, Danielle L., Sahakian, Eva, Wei, Sheng, Djeu, Julie Y.·2010·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-10-0733PMC PMC3874864

Open this paper in CoChat — free account

Abstract

Purpose: Myeloid-derived suppressor cells (MDSC) accumulate in tumor-bearing hosts and are associated with immune suppression. To date, there have only been few studies that evaluate the direct effect of chemotherapeutic agents on MDSCs. Agents that inhibit MDSCs may be useful in the treatment of patients with various cancers. Experimental Design: We investigated the in vivo effects of docetaxel on immune function in 4T1-Neu mammary tumor-bearing mice to examine if a favorable immunomodulatory effect accompanies tumor suppression. Primary focus was on the differentiation status of MDSCs and their ability to modulate T-cell responses. Results: Docetaxel administration significantly inhibited tumor growth in 4T1-Neu tumor-bearing mice and considerably decreased MDSC proportion in the spleen. The treatment also selectively increased CTL responses. Docetaxel-pretreated MDSCs cocultured with OT-II splenocytes in the presence of OVA323-339 showed OT-II–specific CD4 activation and expansion in vitro. In characterizing the phenotype of MDSCs for M1 (CCR7) and M2 [mannose receptor (CD206)] markers, MDSCs from untreated tumor bearers were primarily MR+ with few CCR7+ cells. Docetaxel treatment polarized MDSCs toward an M1-like phenotype, resulting in 40% of MDSCs expressing CCR7 in vivo and in vitro, and macrophage differentiation markers such as MHC class II, CD11c, and CD86 were upregulated. Interestingly, docetaxel induced cell death selectively in MR+ MDSCs while sparing the M1-like phenotype. Finally, inhibition of signal transducer and activator of transcription 3 may in part be responsible for the observed results. Conclusions: These findings suggest potential clinical benefit for the addition of docetaxel to current immunotherapeutic protocols. Clin Cancer Res; 16(18); 4583–94. ©2010 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-0733

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Taxol stabilizes microtubules in mouse fibroblast cells.
Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J., Nagaraj, S., Collazo, M. M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,340
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,258
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E. S., Cole, D. J., & Montero, A. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,217
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054

Show all 42 references

Sorted by citations

Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 3,058
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 951
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 901
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 858
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Emens, L. A., & Middleton, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0064 · Cited by 840
Cell death-based treatment of lung adenocarcinoma
Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0063-y · Cited by 768
Vaccines for established cancer: overcoming the challenges posed by immune evasion
van der Burg, S. H., Arens, R., OSSENDORP, F. A., van Hall, T., & Melief, C. J. M. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.16 · Cited by 731
Macrophages and cancer: from mechanisms to therapeutic implications
Ostuni, R., Kratochvill, F., Murray, P. J., & Natoli, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.004 · Cited by 709
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 708
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy
Pilon-Thomas, S., Kodumudi, K. N., El-Kenawi, A. E., Russell, S., Weber, A. M., Luddy, K., Damaghi, M., Wojtkowiak, J. W., Mulé, J. J., Ibrahim-Hashim, A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1743 · Cited by 593
Self-citation
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
Heinhuis, K. M., Ros, W., Kok, M., Steeghs, N., Beijnen, J. H., & Schellens, J. H. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy551 · Cited by 563
Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy
Hughes, R., Qian, B., Rowan, C., Muthana, M., Keklikoglou, I., Olson, O. C., Tazzyman, S. J., Danson, S. J., Addison, C., Clemons, M. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3587 · Cited by 531
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Law, A. M. K., Valdes-Mora, F., & Gallego-Ortega, D. (2020) · Cells · doi:10.3390/cells9030561 · Cited by 455
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 457
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Fleming, V., Hu, X., Weber, R., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00398 · Cited by 457
Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer
Alizadeh, D., Trad, M., Hanke, N. T., Larmonier, C. B., Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1545 · Cited by 416
Towards targeting the breast cancer immune microenvironment
Harris, M. A., Savas, P. S., Virassamy, B., O’Malley, M. M. R., Kay, J., Mueller, S. N., Mackay, L. K., Salgado, R., & Loi, S. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00714-6 · Cited by 409
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 359
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion
Cicco, P. D., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 341
Tumor‐Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel‐Enhanced Immunotherapy with Polarization toward M1‐Type Macrophages on Triple Negative Breast Cancers
Chen, L., Zhou, L., Wang, C., Han, Y., Lu, Y., Liu, J., Hu, X., Yao, T., Lin, Y., Liang, S., et al. (2019) · Advanced Materials · doi:10.1002/adma.201904997 · Cited by 337
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00482-6 · Cited by 336
Interaction of tumor-associated macrophages and cancer chemotherapy
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596004 · Cited by 322
Therapeutic Cancer Vaccines: Current Status and Moving Forward
Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282
Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer
Li, L., Wang, L., Li, J., Fan, Z., Li, Y., Zhang, Z., Zhang, C., Yue, D., Qin, G., Zhang, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2460 · Cited by 267
Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy
He, S., Zheng, L., & Qi, C. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02208-3 · Cited by 254
Immunotherapy of Prostate Cancer: Facts and Hopes
Bilušić, M., Madan, R. A., & Gulley, J. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0019 · Cited by 253
IL-33 Expands Suppressive CD11b+ Gr-1int and Regulatory T Cells, including ST2L+ Foxp3+ Cells, and Mediates Regulatory T Cell-Dependent Promotion of Cardiac Allograft Survival
Turnquist, H. R., Zhao, Z., Rosborough, B. R., Liu, Q., Castellaneta, A., Isse, K., Wang, Z., Lang, M. A., Stolz, D. B., Zheng, X. X., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100519 · Cited by 244
Chemoimmunotherapy: Reengineering Tumor Immunity
Chen, G., & Emens, L. A. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1388-0 · Cited by 242
Nivolumab in NSCLC: latest evidence and clinical potential
Sundar, R., Cho, B. C., Brahmer, J. R., & Soo, R. A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014567470 · Cited by 234
Current Status and Future Directions
Ito, F., & Chang, A. E. (2013) · Cited by 223
The multifaceted immune regulation of bladder cancer
Schneider, A. K., Chevalier, M. F., & Derré, L. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0226-y · Cited by 222
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Vermaelen, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00008 · Cited by 223
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Planes-Laine, G., Rochigneux, P., Bertucci, F., Chrétien, A.-S., Viens, P., Sabatier, R., & Gonçalvès, A. (2019) · Cancers · doi:10.3390/cancers11071033 · Cited by 227
Tumor-associated myeloid cells: diversity and therapeutic targeting
Mantovani, A., Marchesi, F., Jaillon, S., Garlanda, C., & Allavena, P. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00613-4 · Cited by 230
Immunogenic Cell Death Inducing Metal Complexes for Cancer Therapy
Zhang, L., Montesdeoca, N., Karges, J., & Xiao, H. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202300662 · Cited by 217
Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
Bruno, A., Mortara, L., Baci, D., Noonan, D. M., & Albini, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00771 · Cited by 223
The Tumor Immune Contexture of Prostate Cancer
Vitkin, N., Nersesian, S., Siemens, D. R., & Koti, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00603 · Cited by 218
Cancer‐promoting tumor‐associated macrophages: New vistas and open questions
Mantovani, A., Germano, G., Marchesi, F., Locatelli, M., & Biswas, S. K. (2011) · European Journal of Immunology · doi:10.1002/eji.201141894 · Cited by 211
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Leonetti, A., Wever, B. M. M., Mazzaschi, G., Assaraf, Y. G., Rolfo, C. D., Quaini, F., Tiseo, M., & Giovannetti, E. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100644 · Cited by 202
Tumor-Associated Macrophages as Target for Antitumor Therapy
Sawa-Wejksza, K., & Kandefer‐Szerszeń, M. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0480-8 · Cited by 207
Recent Progress in GM-CSF-Based Cancer Immunotherapy
Yan, W.-L., Shen, K., Tien, C.-Y., Chen, Y., & Liu, S. (2017) · Immunotherapy · doi:10.2217/imt-2016-0141 · Cited by 199
Tumor-Associated Macrophages as Multifaceted Regulators of Breast Tumor Growth
Munir, M. T., Kay, M., Kang, M.-H., Rahman, M. M., Al‐Harrasi, A., Choudhury, M., Moustaïd‐Moussa, N., Hussain, F., & Rahman, S. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126526 · Cited by 198
TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients
Hossain, D. M. S., Pal, S. K., Moreira, D., Duttagupta, P. A., Zhang, Q., Won, H., Jones, J. O., D’Apuzzo, M., Forman, S. J., & Kortylewski, M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3145 · Cited by 192
Chemoresistance of Cancer Cells: Requirements of Tumor Microenvironment-mimicking In Vitro Models in Anti-Cancer Drug Development
Jo, Y., Choi, N., Kim, K., Koo, H., Choi, J. H., & Kim, H. N. (2018) · Theranostics · doi:10.7150/thno.29098 · Cited by 188
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer
Bancaro, N., Calì, B., Troiani, M., Elia, A. R., Arzola, R. A., Attanasio, G., Lai, P., Crespo, M., Gürel, B., Pereira, R., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.004 · Cited by 189
Tumor-Associated Macrophage Status in Cancer Treatment
Malfitano, A. M., Pisanti, S., Napolitano, F., Somma, S. D., Martinelli, R., & Portella, G. (2020) · Cancers · doi:10.3390/cancers12071987 · Cited by 185
Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment
Li, J. J. X., Tsang, J. Y., & Tse, G. M.-K. (2021) · Cancers · doi:10.3390/cancers13164233 · Cited by 190
Paired Immunoglobin-like Receptor-B Regulates the Suppressive Function and Fate of Myeloid-Derived Suppressor Cells
Ma, G., Pan, P., Eisenstein, S. G., Divino, C. M., Lowell, C. A., Takai, T., & Chen, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.004 · Cited by 175
Biological Effects of Nanoparticles on Macrophage Polarization in the Tumor Microenvironment
Reichel, D., Tripathi, M., & Perez, J. M. (2018) · Nanotheranostics · doi:10.7150/ntno.30052 · Cited by 178
Whole Cell Vaccines—Past Progress and Future Strategies
Keenan, B. P., & Jaffee, E. M. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.007 · Cited by 167
Curcumin Induces the Differentiation of Myeloid-Derived Suppressor Cells and Inhibits Their Interaction with Cancer Cells and Related Tumor Growth
Tu, S. P., Jin, H., Shi, J. D., Zhu, L. M., Suo, Y., Lü, G., Liu, A., Wang, T. C., & Yang, C. S. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0247 · Cited by 167
Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer
Dominguez, C. L., McCampbell, K. K., David, J. M., & Palena, C. (2017) · JCI Insight · doi:10.1172/jci.insight.94296 · Cited by 169
Adverse Immunoregulatory Effects of 5FU and CPT11 Chemotherapy on Myeloid-Derived Suppressor Cells and Colorectal Cancer Outcomes
Kanterman, J., Sade-Feldman, M., Biton, M., Ish‐Shalom, E., Lasry, A., Goldshtein, A., Hubert, A., & Baniyash, M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0657 · Cited by 166
TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages
Liu, Z., Xie, Y., Xiong, Y., Liu, S., Qiu, C., Zhu, Z., Mao, H., Yu, M., & Wang, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.020 · Cited by 165
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner
Michels, T., Shurin, G. V., Naiditch, H., Sevko, A., Umansky, V., & Shurin, M. R. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2011.642418 · Cited by 158
Targeting immune checkpoints in breast cancer: an update of early results
Solinas, C., Gombos, A., Latifyan, S., Piccart, M. J., Kok, M., & Buisseret, L. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000255 · Cited by 157
Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer
Opzoomer, J. W., Sosnowska, D., Anstee, J. E., Spicer, J. F., & Arnold, J. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01654 · Cited by 155
Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics
Miyauchi, S., Kim, S. S., Pang, J., Gold, K. A., Gutkind, J. S., Califano, J. A., Mell, L. K., Cohen, E. E. W., & Sharabi, A. B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0871 · Cited by 151
Antibody–Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies
Rios‐Doria, J., Harper, J. W., Rothstein, R. P., Wetzel, L. K., Chesebrough, J. W., Marrero, A. M., Chen, C., Strout, P., Mulgrew, K. A., McGlinchey, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2854 · Cited by 150
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer
Janjigian, Y. Y., Cutsem, E. V., Muro, K., Wainberg, Z. A., Al‐Batran, S., Hyung, W. J., Molena, D., Marcovitz, M., Ruscica, D., Robbins, S. H., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0093 · Cited by 152
Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy
Sasso, M. S., Lollo, G., Pitorre, M., Solito, S., Pinton, L., Valpione, S., Bastiat, G., Mandruzzato, S., Bronte, V., Marigo, I., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.010 · Cited by 150
Clinical Perspectives on Targeting of Myeloid Derived Suppressor Cells in the Treatment of Cancer
Najjar, Y. G., & Finke, J. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00049 · Cited by 146
Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells
Alizadeh, D., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0301 · Cited by 142
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
Coffelt, S. B., & de Visser, K. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.006 · Cited by 147
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy
Joshi, S., & Sharabi, A. B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108114 · Cited by 143
Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines
Butt, A., & Mills, K. H. G. (2013) · Oncogene · doi:10.1038/onc.2013.432 · Cited by 145
PlatinER: A Highly Potent Anticancer Platinum(II) Complex that Induces Endoplasmic Reticulum Stress Driven Immunogenic Cell Death
Tham, M. J. R., Babak, M. V., & Ang, W. H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008604 · Cited by 138
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
Podrazil, M., Horváth, R., Becht, É., Rožková, D., Bílková, P., Sochorová, K., Hromádková, H., Kayserová, J., Vávrová, K., Lašťovička, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4145 · Cited by 136
β‐Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid‐derived suppressor cells
Tian, J., Ma, J., Ma, K., Guo, H., Baidoo, S. E., Zhang, Y., Yan, J., Lu, L., Xu, H., & Wang, S. (2013) · European Journal of Immunology · doi:10.1002/eji.201242841 · Cited by 134
Targeting tumor associated macrophages: The new challenge for nanomedicine
Andón, F. T., Digifico, E., Maeda, A., Erreni, M., Mantovani, A., Alonso, M. J., & Allavena, P. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.004 · Cited by 131
Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments
Cuzzubbo, S., Mangsbo, S. M., Nagarajan, D., Habra, K., Pockley, A. G., & McArdle, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.615240 · Cited by 131
Tumor‐infiltrating CD14‐positive myeloid cells and CD8‐positive T‐cells prolong survival in patients with cervical carcinoma
van Steenwijk, P. J. D. V., Ramwadhdoebé, T. H., Goedemans, R., Doorduijn, E. M., van Ham, J. J., Gorter, A., van Hall, T., Kuijjer, M. L., van Poelgeest, M. I. E., van der Burg, S. H., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28309 · Cited by 130
Combinatorial prospects of nano-targeted chemoimmunotherapy
Silva, C. G. D., Rueda, F., Löwik, C. W. G. M., OSSENDORP, F. A., & Cruz, L. J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.006 · Cited by 128
Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles
Zhang, M., Kim, J. A., & Huang, A. Y.-C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00341 · Cited by 130
The Anthelmintic Drug Niclosamide Induces Apoptosis, Impairs Metastasis and Reduces Immunosuppressive Cells in Breast Cancer Model
Ye, T., Xiong, Y., Yan, Y., Xia, Y., Song, X., Liu, L., Li, D., Wang, N., Zhang, L., Zhu, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085887 · Cited by 126
Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
Heeke, A. L., & Tan, A. R. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09972-4 · Cited by 131
Drug delivery to macrophages: Challenges and opportunities
Pei, Y., & Yeo, Y. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.014 · Cited by 129
Tumor-associated macrophages and anti-tumor therapies: complex links
Belgiovine, C., D’Incalci, M., Allavena, P., & Frapolli, R. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2166-5 · Cited by 126
Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
Ma, Z., Zhang, W., Dong, B., Xin, Z., Ji, Y., Su, R., Shen, K., Pan, J., Wang, Q., & Xue, W. (2022) · Theranostics · doi:10.7150/thno.73152 · Cited by 127
Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer
Malesci, A., Bianchi, P., Celesti, G., Basso, G., Marchesi, F., Grizzi, F., Di Caro, G., Cavalleri, T., Rimassa, L., Palmqvist, R., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1342918 · Cited by 124
Chemotherapy and tumor microenvironment of pancreatic cancer
Liu, Q., Liao, Q., & Zhao, Y. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0437-3 · Cited by 120
Nifuroxazide induces apoptosis and impairs pulmonary metastasis in breast cancer model
Yang, F., Hu, M., Lei, Q., Xia, Y., Zhu, Y., Song, X., Li, Y., Jie, H., Liu, C., Xiong, Y., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.63 · Cited by 118
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer
Tsao, M., Teuff, G. L., Shepherd, F. A., Landais, C., Hainaut, P. L., Filipits, M., Pirker, R., Chevalier, T. L., Graziano, S. L., Kratze, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx003 · Cited by 116
Role of Tumor-Associated Myeloid Cells in Breast Cancer
Cha, Y. J., & Koo, J. S. (2020) · Cells · doi:10.3390/cells9081785 · Cited by 114
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 115
Tumor-associated macrophages as an emerging target against tumors: Creating a new path from bench to bedside
Jinushi, M., & Komohara, Y. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.01.002 · Cited by 115
Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
Sutherland, S., Ju, X., Horvath, L. G., & Clark, G. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641307 · Cited by 115
Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma
Kodumudi, K. N., Weber, A. M., Sarnaik, A. A., & Pilon‐Thomas, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200274 · Cited by 113
Self-citation
Chronic inflammation and cancer: suppressing the suppressors
Baniyash, M., Sade-Feldman, M., & Kanterman, J. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1468-9 · Cited by 111
Antigen-Specific CD4+ T Cells Regulate Function of Myeloid-Derived Suppressor Cells in Cancer via Retrograde MHC Class II Signaling
Nagaraj, S., Nelson, A., Youn, J., Cheng, P., Quiceno, D. G., & Gabrilovich, D. I. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2863 · Cited by 104
Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non–Small Cell Lung Cancer
Koinis, F., Vetsika, E., Aggouraki, D., Skalidaki, E., Koutoulaki, A., Gkioulmpasani, M., Georgoulias, V., & Kotsakis, A. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.026 · Cited by 102
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
Law, A. M. K., Lim, E., Ormandy, C. J., & Gallego‐Ortega, D. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0404 · Cited by 103
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
Zhou, Y., Chen, C., Zhang, X., Fu, S., Xue, C., Ma, Y., Fang, W., Yang, Y., Hou, X., Huang, Y., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0477-9 · Cited by 102
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Datsi, A., & Sorg, R. V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.770390 · Cited by 105

Authors: Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., & Djeu, J. Y.
Affiliations: Moffitt Cancer Center (US)
Authors' Affiliation: Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida
Corresponding author: Djeu, Julie Y.
ORCID: Kodumudi, Krithika N.
Woan, Karrune
Sahakian, Eva
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2010-09-14
Volume: 16
Issue: 18
Pages: 4583-4594
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-10-0733
PMC: PMC3874864
OpenAlex: W2143994426
Cited by: 500
References: 42
Citations by year: 2026: 6 · 2025: 14 · 2024: 33 · 2023: 32 · 2022: 37 · 2021: 39 · 2020: 39 · 2019: 43 · 2018: 33 · 2017: 38 · 2016: 42 · 2015: 32 · 2014: 31 · 2013: 36 · 2012: 22
FWCI: 10.74
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (T32CA115308)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords: docetaxel, myeloid-derived suppressor cells, tumor immunosuppression, CTL response, CD4+ T cell activation, CD206, CCR7, macrophage differentiation, STAT3 signaling, tumor-bearing mice
MeSH terms: Docetaxel, Animals, Antineoplastic Agents, Cell Differentiation, Cytotoxicity, Immunologic, Female, Immune Tolerance, Immunosuppressive Agents, Lymphocyte Activation, Mice, Inbred BALB C, Mice, Transgenic, Neoplasm Transplantation, Neoplasms, T-Lymphocytes, Myeloid Cells, Taxoids, Cell Line, Tumor, Mice, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks